[{"address1": "Yalelaan 60", "city": "Utrecht", "zip": "3584 CM", "country": "Netherlands", "phone": "31 630 00 30 35", "website": "https://www.lavatherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.", "fullTimeEmployees": 69, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stephen Allen Hurly M.B.A., M.Sc.", "age": 55, "title": "CEO, President & Executive Director", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Fred M. Powell CPA", "age": 62, "title": "Chief Financial Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hans  van der Vliet M.D., Ph.D.", "age": 49, "title": "Chief Scientific Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Amy  Garabedian J.D.", "age": 47, "title": "General Counsel & Corporate Secretary", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Wouter van Hunnik", "title": "VP & Head of Human Resources", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ton  Adang Ph.D.", "age": 62, "title": "Chief Development Officer", "yearBorn": 1961, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.47, "open": 2.54, "dayLow": 2.32, "dayHigh": 2.76, "regularMarketPreviousClose": 2.47, "regularMarketOpen": 2.54, "regularMarketDayLow": 2.32, "regularMarketDayHigh": 2.76, "beta": 0.632, "forwardPE": -1.6235293, "volume": 346054, "regularMarketVolume": 346054, "averageVolume": 1775210, "averageVolume10days": 5666620, "averageDailyVolume10Day": 5666620, "bid": 2.58, "ask": 2.63, "bidSize": 1400, "askSize": 1000, "marketCap": 72557912, "fiftyTwoWeekLow": 1.131, "fiftyTwoWeekHigh": 6.47, "priceToSalesTrailing12Months": 8.012136, "fiftyDayAverage": 1.92666, "twoHundredDayAverage": 1.751255, "currency": "USD", "enterpriseValue": -33497956, "floatShares": 12101655, "sharesOutstanding": 26289100, "sharesShort": 55922, "sharesShortPriorMonth": 87744, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0021, "heldPercentInsiders": 0.28581, "heldPercentInstitutions": 0.33103, "shortRatio": 0.03, "shortPercentOfFloat": 0.0056, "impliedSharesOutstanding": 26289100, "bookValue": 2.077, "priceToBook": 1.3288398, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -50391000, "trailingEps": -1.92, "forwardEps": -1.7, "enterpriseToRevenue": -3.699, "enterpriseToEbitda": 0.688, "52WeekChange": 0.43604648, "SandP52WeekChange": 0.32974386, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "LVTX", "underlyingSymbol": "LVTX", "shortName": "LAVA Therapeutics N.V.", "longName": "LAVA Therapeutics N.V.", "firstTradeDateEpochUtc": 1616765400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f272303e-4305-36b0-b7df-26c82acd7c44", "messageBoardId": "finmb_546792242", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.76, "targetHighPrice": 11.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.8, "targetMedianPrice": 6.0, "recommendationMean": 1.4, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 104627000, "totalCashPerShare": 3.98, "ebitda": -48668000, "totalDebt": 6195000, "quickRatio": 5.108, "currentRatio": 5.2, "totalRevenue": 9056000, "debtToEquity": 11.347, "revenuePerShare": 0.344, "returnOnAssets": -0.23615, "returnOnEquity": -0.68441004, "freeCashflow": 23552750, "operatingCashflow": 6883000, "revenueGrowth": -0.997, "operatingMargins": -202.39622, "financialCurrency": "USD", "trailingPegRatio": null}]